Investigation, treatment and monitoring of late-onset hypogonadism in males. Official Recommendations of ISSAM

References

• Morales A, Lunenfeld B. Androgen replacement therapy in aging men with secondary hypogonad-ism. Draft recommendations for endorsement by ISSAM. Aging Male 2001;4:151–62
   Google Scholar
• Kaufman JM. Hypothalamic-pituitary-gonadal funtion in aging men. Aging Male 1999;2:157
   Google Scholar
• Werner AA. The male climacteric. J Am Med Assoc 1946;132:188
   Google Scholar
• Morley JE, Charlton E, Patrick P, et al. Validation of a screening questionnaire for androgen defi-ciency in aging males. Metabolism 2000;49:1239
   Google Scholar
• Heinemann LAJ, Saad F, Thiele K, Wood-Duphenee S. The Aging Males’ Symptom rating scale: cultural and linguistic validation into English. Aging Male 2001;4:14–22
   Google Scholar
• Vermeulen A, Kaufman JM. Aging of the hypothalamo-pituitary-testicular axis in men. Horm Res 1995;43:25
   Google Scholar
• Vermeulen A, Verdonck L, Kaufman JL. A critical evaluation of simple methods for the estimation of free hormones in serum. J Clin Endocrinol Metab 1999;84:3666
   Google Scholar
• Morales A, Heaton JPW. Hormonal erectile dysfunction: evaluation and management. Urol Clin NA 2001;28:279
   Google Scholar
• Alexander GM, Swerdloff RS, Wang C, Davidson T, McDonald V, Steiner B, et al. Androgen behavior correlations in hypogonadal and eugonadal men: cognitive abilities. Horm Behav 1998;33:85
   Google Scholar
• Urban RJ, Bodenburg YH, Gilkison C, Fowworth J, Coggan AR, Wolfe RR. Testosterone administration to elderly men increases skeletal muscle strength and protein synthesis. Am J Physiol 1995;269:820
   Google Scholar
• Tenover JS. Androgen administration to aging men. Endocrinol Metab Clin NA 1994;23:877
   Google Scholar
• Hibberts NA, Howell AE, Randall VA. Balding hair follicle dermal papilla cells contain higher levels of androgen receptors than those from non-balding scalp. J Endocrinol 1998;156:59
   Google Scholar
• Behre HM, Kliesch S, Leifke E, Link TM, Nieschlag E. Long term effect of testosterone therapy on bone mineral density in hypogonadal men. J Clin Endocrinol Metab 1997;82:2386
   Google Scholar
• Kropman RF, Verdijk RM, Lyklama AAB, Nijeholt A, Roelfsma F. Routine endocrine screening in impotence: significance and cost-effectiveness. Int J Impotence Res 1991;3:87
   Google Scholar
• Vermeulen A. Routine endocrine screening in impotence: significance and cost effectiveness. [Editorial]. Int J Impotence Res 1991;3:85
   Google Scholar
• Buvat J, Lemaire A. Endocrine screening in 1022 men with erectile dysfunction: clinical significance and cost-effective strategy. J Urol 1997;158:1764
   Google Scholar
• Morales A, Johnston B, Heaton JWP, Lundie M. Testosterone supplementation in hypogonadal impotence: assessment of biochemical measure-ments and therapeutic outcomes. J Urol 1997;157: 849
   Google Scholar
• Tremblay RR. Practical consequences of the validation of a mathematical model in assessment of partial androgen deficiency in the aging male using bioavailable testosterone. Aging Male 2001;4:23–9
   Google Scholar
• Herbert J. The age of dehydroepiandrosterone. Lancet 1995;345:1193
   Google Scholar
• Morales AJ, Nolan JJ, Nelson JC, et al. Effects of replacement dose of dehydroepiandrosterone in men and women of advancing age. J Clin Endocrinol Metab 1994;78:1360
   Google Scholar
• Arlt W, Callies F, Koehler L, et al. Dehydroepi-androsterone supplementation in healthy men with an age related decline of dehydroepiandrosterone secretion. J Clin Endocrinol Metab 2001;86:4686
   Google Scholar
• Vaughn ED, Cox DS. Chronic administration of dehydroepiandrosterone (DHEA) does not increase serum testosterone or prostatic specific antigen (PSA) in normal men. J Urol 1998;159: 27(abstr 280)
   Google Scholar
• Christiansen KH. Behavioral correlates of dehydroepiandrosterone and dehydroepiandro-sterone sulfate. Aging Male 1998;1:103–12
   Google Scholar
• Weksler ME. Hormone replacement for men - not enough evidence to recommend routine treatment with dehydroepiandrosterone. Br Med J 1996;312: 859
   Google Scholar
• deBoer H, Block GJ, van der Veen EA. Clinical aspects of growth hormone deficiency in adults. Endocrinol Rev 1995;16:63
   Google Scholar
• Veldhuis JD. Elements in the pathophysiology of diminished growth hormone (GH) secretion in aging humans Endocrinology 1996;7:41
   Google Scholar
• Holmes SJ, Economou G, Whitehouse RW, Adams JE, Shalet SM. Reduced bone mineral density in patients with adult onset growth hormone deficiency. J Clin Endocrinol Metab 1994;78:669
   Google Scholar
• Block GJ, de Boer H, Gooren LJG, van der Veen EA. Growth hormone substitution in adult growth-hormone deficient men augments andro-gen effect on the skin. Clin Endocrinol 1997;47:29
   Google Scholar
• Baum HB, Biller BMK, Finkelstein JS, Cannistraro KB, Oppenheim DS, Schonfeld DA, et al. Effects of physiologic growth hormone therapy on bone density and body composition in patients with adult-onset growth hormone deficiency. A randomized placebo controlled trial. Ann Intern Med 1996;125:883
   Google Scholar
• Lesee GP, Frase WD, Farqhuarson R, Hipkin L, Vora JI. Gonadal status is an important determinant of bone density in acromegaly. Clin Endocrinol 1998;48:59
   Google Scholar
• Liu R-Y, Zhou J-N, van Heerikhuize J, Hofman MA, Swaab DF. Decreased melatonin levels in post-mortem cerebro-spinal fluid in relation to ageing, Alzheimer’s disease and apoliprotein E-e4/4 genotype. J Clin Endocrinol Metab 1999; 84:323
   Google Scholar
• Dittgen M, Hoffmann H. New dosage form for pulsatile delivery of melatonin: development and testing in animal and human subjects. Aging Male 1998;1:141–8
   Google Scholar
• Sewerynek E, Melchirri D, Reiter RJ, Ortiz GG, Lewinski A. Lipopolysaccharide-induced hepato-toxicity is inhibited by the antioxidant melatonin. Eur J Pharmacol 1995;293:327
   Google Scholar
• Maestroni GJM. The immunoneuroendocrine role of melatonin. J Pineal Res 1993;14:1
   Google Scholar
• Olcese J. Melatonin and the aging male. Aging Male 1998;1(Suppl 1):9
   Google Scholar
• Olcese J. Cellular and molecular mechanisms mediating melatonin action. Aging Male 1998;1:113–28
   Google Scholar
• Samuels H, Pekary AE, Hershman JM. Hypotha-lamic-pituitary-thyroid axis in aging. In Morley JE, van den Berg L, eds. Endocrinology of Aging. Totowa, NJ: Humana Press, 2000:41–62
   Google Scholar
• Bray GA, York DA. Leptin and clinical medicine: a new piece in the puzzle of obesity. J Clin Endocrinol Metab 1997;82:2771
   Google Scholar
• Luukkaa V, Personen U, Huhtaniemi I, Lehtonen A, Tilvis R, Tuomilehto J, et al. Inverse correlation between serum testosterone and leptin in men. J Clin Endocrinol Metab 1998;83:3243
   Google Scholar
• Behre HM, Simoni M, Nieschlag E. Strong association between leptin and testosterone. Clin Endocrinol 1997;47:237
   Google Scholar
• Finkelstein JS, Kilbanski A, Neer RM, Doppelt SH, Rosenthal DI, Segre GV, et al. Increases in bone density during treatment of men with idio-pathic hypogonadotrophic hypogonadism. J Clin Endocrinol Metab 1989;69:776
   Google Scholar
• Gooren LJG. Long-term safety of the oral androgen testosterone undecanoate. Int J Androl 1986;9:21
   Google Scholar
• Gooren LJG. Long term safety of the oral androgen testosterone undecanoate. J Androl 1994;15:212
   Google Scholar
• Bagatell CJ, Bremner WJ. Drug therapy: androgens in men - uses and abuses. New Engl J Med 1996;334:707–11
   Google Scholar
• Sokol RZ, Palacios A, Campfield LA. Comparison of the kinetics of injectable testosterone in eugonadal and hypogonadal men. Fertil Steril 1982; 37:425–30
   Google Scholar
• Bhasin S. Androgen treatment of hypogonadal men. J Clin Endocrinol Metab 1992;74:1221–4
   Google Scholar
• Morales A, Heaton JWP, Carson CC III. Andropause: a misnomer for a true clinical entity. J Urol 2000;163:705–12
   Google Scholar
• Bhasin S, Bremner WJ. Emerging issues in andro-gen replacement therapy. J Clin Endocrinol Metab 1997;82:3–7
   Google Scholar
• Yates WR, Perry PJ, MacIndoe J, Holman T, Ellingrod V. Psychosexual effects of 3 doses of testosterone cycling in normal men. Biol Psychiatr 1999;45:254–60
   Google Scholar
• Bradwin SW, Swerdloff RS, Santen RJ. Andro-gens: risks and benefits. J Clin Endocrinol Metab 1991;73:4–7
   Google Scholar
• Arver S, Meikle AW, Dobbs AS, et al. Permeation enhanced testosterone transdermal systems in the treatment of male hypogonadism: long term effects. J Endocrinol 1996;148:254–9
   Google Scholar
• De Sanctis V, Vullo C, Urso L, et al. Clinical expe-rience using Androderm testosterone transdermal system in hypogonadal adolescents and young men with beta-thalassemia major. J Pediatr Endocrinol Metab 1999;11(Suppl 3):891-900
   Google Scholar
• Dobbs AS, Meikle AW, Arver S, et al. Pharma-cokinetics, efficacy and safety of permeation-enhanced testosterone transdermal system in comparison with bi-weekly injections of testoster-one enanthate for the treatment of hypogonadal men, J Clin Endocrinol Metab 1999;84:3469–78
   Google Scholar
• Wang C, Swerdloff RS, Iranmanesh A, Dobbs A, Snyder PJ, Gunningham G, et al. Transdermal testosterone gel improves sexual function, mood, muscle strength and body composition parameters in hypogonadal men. J Clin Endocrinol Metab 2000; 85:2839
   Google Scholar
• Ly LP, Jimenez M, Zhuang TN, Celermajer DS, Conway AJ, Handelsman DJ. A double-blind, placebo-controlled, randomized clinical trial of transdermal dihydrotestosterone gel on muscular strength, mobility, and quality of life in older men with partial androgen deficiency. J Clin Endocrinol Metab 2001;86:4078–88
   Google Scholar
• Kunelius P, Lukkarinen O, Hannuksela ML, Itkonen O, Tapanainen JS. The effects of trans-dermal dihydrotestosterone in the aging male: a prospective, randomized, double blind study. J Clin Endocrinol Metab 2002;87:1467–72
   Google Scholar
• Zmuda JM, Cauley JA, Kriska A. Longitudinal relation between endogenous testosterone and cardiovascular disease risk factors in middle age men. A 13 year follow-up of former risk factor intervention trial participants. Am J Epidemiol 1997; 146:609–15
   Google Scholar
• Phillips GB. The association of hypotestos-teronemia with coronary artery disease in men. Arterioscler Thromb 1994;14:701–5
   Google Scholar
• Uyanik BS, Ari Z, Gumus B, et al. Beneficial effects of testosterone undecanoate on the lipoprotein profiles in healthy elderly men. Jpn Heart J 1997; 38:73–7
   Google Scholar
• Crook D. Androgens and the risk of cardiovascular disease. Aging Male 2000;3:190–5
   Google Scholar
• Gooren LJG. Visceral obesity, androgens and the risk of cardiovascular disease and diabetes mellitus. Aging Male 2001;4:30–8
   Google Scholar
• Tenover JL. Testosterone and the aging male. J Androl 1997;18:103–6
   Google Scholar
• Behre HM. Prostate volume in treated and untreated hypogonadal men in comparison to age matched controls. Clin Endocrinol 1994;40:341–6
   Google Scholar
• Cooper CS, Perry PJ, Sparks AE, et al. Effects of exogenous testosterone on prostate volume, serum and semen prostate specific antigen levels in healthy young men. J Urol 1998;159:441–3
   Google Scholar
• Holmäng S, Marin P, Lindtstedt G, et al. Effect of long term oral testosterone undecanoate treatment on prostate volume and serum prostate specific antigen in eugonadal middle-aged men. Prostate 1993;23:99–106
   Google Scholar
• Nomura A, Heilrunn LK, Stemmermann GN, et al. Prediagnostic serum hormones and the risk of prostate cancer. Cancer Res 1998;48:3515–20
   Google Scholar
• Curran MJ, Bihrle W. Dramatic raise in prostate specific antigen after androgen replacement in a hypogonadal man with occult adenocarcinoma of the prostate. Urology 1999;53:423–4
   Google Scholar
• Morales A. Androgen replacement therapy and prostate safety Eur Androl 2002;37:1
   Google Scholar
• Wang C, Alexander G, Berman N, et al. Testos-terone replacement therapy improves mood in hypogonadal men - a clinical research center study. J Clin Endocrinol Metab 1996;81:3587–93
   Google Scholar
• Ehrenreich H, Halaris A, Ruether E, et al. Psychoendocrine sequelae of chronic testosterone deficiency. J Psychiatr Res 1999;33:379–87
   Google Scholar
• Ozata M, Odabasi Z, Caglayan S, et al. Event related male potentials in male hypogonadism. J Endocrinol Invest 1999;22:508–13
   Google Scholar
• Sternbach H. Age associated testosterone decline in men: clinical issues for psychiatry. Am J Psychiatr 1998;155:1310–14
   Google Scholar
• Morales A, Connolly J, Burr R, et al. The use of radioactive phosphorus to treat bone pain in metastatic carcinoma of the prostate. Can Med Assoc J 1970;103:372–3
   Google Scholar
• Tennover L. Androgen deficiency in the aging male. Presented at Postgraduate Course, American Urological Association, May, 2000
   Google Scholar
• Krauss DJ, Taub HA, Lantiga LJ. Risk of blood volume changes in hypogonadal men treated with testosterone enanthate for erectile impotence. J Urol 1991;146:1566–70
   Google Scholar
• Sandbloom RA, Matsumoto AM, Schoene RB, et al. Obstructive sleep apnea syndrome induced by testosterone administration. N Engl J Med 1983; 308:508–10
   Google Scholar
• Santamaria JD, Prior JC, Fleetham JA. Reversible reproductive dysfunction in men with sleep apnea. Clin Endocrinol (Oxf) 1988;28:461–70
   Google Scholar
• Behre HM, Kliesch S, Leifke E, Link TM, Nieschlag E. Long-term effect of testosterone therapy on bone mineral density in hypogonadal men. J Clin Endocrinol Metab 1997;82:2386
   Google Scholar
• Morales A, Bain J, Ruijs A, Chapdelaine A, Tremblay RR. Clinical practice guidelines for screening and monitoring male patients receiving testosterone supplementation therapy. Int J Impotence Res 1996;8:95
   Google Scholar
• Tremblay RR, Morales A. Canadian practice recommendations for screening, monitoring and treating men affected by andropause or partial androgen deficiency. Aging Male 1998;1:213–18
   Google Scholar
• Morales A. Canadian practice recommendations for screening, treatment and monitoring of aging men with androgen deficiency. Aging Male 2001; 4(Suppl 1):35-7
   Google Scholar
• Kim YC. Hormonal replacement therapy in men: Korean practical recommendations on testosterone supplementation in the aging male. Aging Male 2001;4(Suppl 1):30-4
   Google Scholar